# US 10,039,784 B2 · Methods of treating a treatment-resistant gastrointestinal spasm with an oxidized tannin > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,039,784 B2 - Document ID: US10039784B2 - Status: Granted - Kind: B2 - Application number: 15/876,361 - Filed: 2018-01-22 - Published: 2018-05-24 - Granted: 2018-08-07 - Earliest claimed: 2012-12-23 - Assignees: LiveLeaf, Inc. - Applicants: LiveLeaf, Inc. - Inventors: Alexander L Huang; Gin Wu - Web page: https://patentgrep.com/patent/US10039784B2 ## CPC - A61K 33/40: Peroxides - A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)} - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin - A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol} - A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages - A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61K 36/185: Magnoliopsida (dicotyledons) - A61K 36/22: Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak - A61K 36/3482: {Cannabis} - A61K 36/742: {Coffea, e.g. coffee} - A61K 36/82: Theaceae (Tea family), e.g. camellia - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Methods of treating a gastrointestinal spasm in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastrointestinal spasm, the formulation having a tannin combined with a hydrogen donor in a pharmaceutically acceptable excipient as a binding pair, the tannin releasing in an oxidized state from the hydrogen donor after oral administration of the formulation in the subject; wherein, the composition at least inhibits a gastrointestinal spasm in the subject when compared to a second subject in a control group in which the composition was not administered. ## Claims ### Claim 1 A method of treating a treatment-resistant gastrointestinal spasm in a subject, the method comprising: orally administering an effective amount of a formulation to treat a gastrointestinal spasm in the subject, the formulation having a binding pair in a pharmaceutically acceptable excipient; wherein, the binding pair is created by a process comprising: selecting a water soluble tannin having a molecular weight ranging from about 170 Daltons to about 4000 Daltons; and, oxidizing the tannin with a hydroxyl radical, the oxidizing including combining the tannin with the hydroxyl radical at a weight ratio ranging from about 1:1000 to about 10:1 to oxidize the tannin and form the binding pair having the oxidized tannin releasably bound to the hydroxyl radical; wherein, the gastrointestinal spasm is a symptom of a condition selected from the group consisting of inflammatory bowel syndrome, Crohn's disease, ulcerative colitis, diverticulitis, colorectal cancer, stress, malnutrition, necrotic enteritis, drug side-effects, chemotherapy, radiation therapy, and gastroesophageal reflux disease; and, the formulation at least inhibits the gastrointestinal spasm when compared to a second subject in a control group in which the formulation was not administered. ### Claim 2 (depends on 1) The method of claim 1, wherein the tannin is a hydrolysable tannin. ### Claim 3 (depends on 1) The method of claim 1, wherein the tannin is a water soluble condensed tannin. ### Claim 4 (depends on 1) The method of claim 1, wherein the tannin is a flavanol. ### Claim 5 (depends on 1) The method of claim 1, wherein the tannin is a catechin. ### Claim 6 (depends on 1) The method of claim 1, wherein the tannin is gallic acid, epigallic acid, or a combination thereof. ### Claim 7 (depends on 1) The method of claim 1, wherein the tannin is a gallotannin. ### Claim 8 (depends on 1) The method of claim 1, wherein the tannin is an ellagitannin. ### Claim 9 (depends on 1) The method of claim 1, wherein the tannin is a punicalagin. ### Claim 10 (depends on 2) The method of claim 2, wherein the hydrolysable tannin is a product of a water extraction of Chinese gall. ### Claim 11 (depends on 1) The method of claim 1, wherein the tannin is a hydrolysable tannin having from 3-12 galloyl residues. ### Claim 12 A method of treating a treatment resistant gastrointestinal spasm in a subject, the method comprising: administering an effective amount of a formulation to treat a gastrointestinal spasm in the subject, the formulation having a water soluble tannin combined with a hydroxyl radical to create a binding pair prior to the administering; wherein, the binding pair is created by a process comprising: selecting a water-soluble tannin having a molecular weight ranging from about 170 Daltons to about 4000 Daltons; oxidizing the tannin with a hydroxyl radical, the oxidizing including combining the tannin with the hydroxyl radical at a weight ratio ranging from about 1:1000 to about 10:1 to form the binding pair having the oxidized tannin releasably bound to the hydroxyl radical; wherein, the gastrointestinal spasm is a symptom of a condition selected from the group consisting of inflammatory bowel syndrome, Crohn's disease, ulcerative colitis, diverticulitis, colorectal cancer, stress, malnutrition, necrotic enteritis, drug side-effects, chemotherapy, radiation therapy, and gastroesophageal reflux disease; and, the formulation at least inhibits the gastrointestinal spasm when compared to a second subject in a control group in which the formulation was not administered. ### Claim 13 (depends on 12) The method of claim 12, wherein the tannin is a water soluble condensed tannin. ### Claim 14 (depends on 12) The method of claim 12, wherein the tannin is a flavanol. ### Claim 15 (depends on 12) The method of claim 12, wherein the tannin is a catechin. ### Claim 16 (depends on 12) The method of claim 12, wherein the tannin is gallic acid, epigallic acid, or a combination thereof. ### Claim 17 (depends on 12) The method of claim 12, wherein the tannin is a gallotannin. ### Claim 18 (depends on 12) The method of claim 12, wherein the tannin is an ellagitannin. ### Claim 19 (depends on 12) The method of claim 12, wherein the tannin is a punicalagin. ### Claim 20 (depends on 12) The method of claim 12, including using a hydroxyl radical concentration ranging from about 0.001% to about 2.0% based on total dry weight of the composition; drying the binding pair under a vacuum; and, storing the dried binding pair for use in creating the formulation to treat irritable bowel syndrome, Crohn's disease, ulcerative colitis, diverticulitis, colorectal cancer, stress, malnutrition, necrotic enteritis, drug side-effects, chemotherapy, radiation therapy, or gastroesophageal reflux disease. ### Claim 21 (depends on 12) The method of claim 12, wherein the tannin is a hydrolysable tannin.